- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Biosimilars Immunology Roundup for May 2023—Podcast Edition
On this episode of Not So Different, we recap some of the biggest stories in the immunology space regarding biosimilars, including a new European approval, ustekinumab biosimilar delays, and more.
On this episode, we’re going to be recapping some of the biggest stories in the immunology space regarding biosimilars, including a new European approval, ustekinumab biosimilar delays, and more.
Show notes
FDA Approves Celltrion’s Yuflyma, the Ninth Adalimumab Biosimilar
Celltrion Launches Biobetter in Brazil, Shares Phase 3 Plan for MS Biosimilar
Amgen’s Stelara Biosimilar Delayed Until 2025 After Settling With J&J
Dr Colby Evans: The Managed Care Perspective on Biosimilars in Immunology
Dr Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings
Samsung Bioepis Report Correlates Biosimilar Pricing Changes With Market Adoption
Biosimilars Business News Recap: A New Partnership; Celltrion Wins Tenders
Tocilizumab Biosimilar LZM008 Demonstrates PK Equivalence in Healthy Participants
RWE: Rituximab Biosimilar GP2013 Effective in Patients With RA After Switching From Originator
Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Remicade in IBD
February 15th 2025Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.
Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
February 9th 2025In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
FDA Approves Celltrion's Avtozma as Third Tocilizumab Biosimilar
January 31st 2025The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions. It is the third biosimilar to reference Actemra (tocilizumab) to be approved for US patients.
